Tether, the leading stablecoin provider using USDT, revealed on Monday that it utilized $200 million to purchase a controlling share in Blackrock Neurotech, a brain-computer interfaces developer company, through Tether Evo, a venture capital division.
Blackrock Neurotech creates brain-signaling powered medical gadgets to assist those suffering from neurological illnesses and paralysis. The tech company and the massive asset management company, BlackRock are unrelated.
Tether hopes to support the marketing and implementation of medical solutions that have already helped over 40 patients. Along with enhancing research and development, Blackrock Neurotech plans to use the funding to stay a significant participant in the BCI space going forward, with a long-term focus on human evolution.
The Blackrock Neurotech is dedicated to assisting millions of individuals worldwide who suffer from neurological illnesses, paralysis, lost function, and other conditions that make it impossible for them to walk, see, hear, feel, or speak.
The company behind USDT, the biggest stablecoin with a $110 billion market capitalization, is Tether. Tether recently created four divisions to grow outside the stablecoin business.
Paolo Ardoino, CEO of Tether, said, “Tether has long believed in nurturing emerging technologies that have transformative capabilities, and the Brain-Computer-Interfaces of Blackrock Neurotech have the potential to open new realms of communication, rehabilitation, and cognitive enhancement.”
He added, “Blackrock Neurotech represents a leap towards a future where technology not only complements but enhances our human experience, and we at Tether are proud to begin this journey with them.”
Co-founder Florian Solzbacher of Blackrock Neurotech pointed out that the company’s goal of assisting people in regaining their functions is a long-term project that calls for committed and creative partners.
Also Read: Tether Expands Dollar & Gold Stablecoins for Telegram’s TON
